Top 46 AI-Enabled Biotech Companies Revolutionizing Healthcare

Here is a list of 46 innovative AI-enabled biotech companies to watch who are making a positive impact on society.  

The Omdena “AI Adoption Leaders Series” comprises game-changing startups, stories, and thought-leadership pieces from leading impact ventures solving real-world problems using AI.

Introduction

Integration of AI in the biotech industry has brought about a revolution in the healthcare sector. 2024 has witnessed a surge in the number of biotechnology companies utilizing artificial intelligence to streamline operations, enhance drug discovery and development, and improve patient outcomes. The use of AI in biotech has opened up new avenues for personalized medicine, predictive diagnostics, and cutting-edge research. In this article, we take a look at the top AI-enabled biotech companies leading the charge in the integration of AI and biotechnology.

What is Biotechnology?

Biotechnology is a branch of biology that uses living organisms, cells, and biological systems to develop new technologies and products. It encompasses a wide range of scientific disciplines, including genetics, molecular biology, microbiology, biochemistry, and chemical engineering, and it has applications in many different fields, such as agriculture, food science, medicine, and environmental protection.

In biotechnology, living organisms and biological systems are used to produce and improve products, processes, and technologies. For example, bacteria and yeast can be used to produce food ingredients, like cheese and bread, and medicines, like insulin. Biotechnology can also be used to clean up environmental pollution and to diagnose and treat diseases.

What is the most important field of biotechnology?

It’s difficult to say which field of biotechnology is the most important as it depends on individual perspectives and priorities. However, some of the most influential and impactful fields of biotechnology include:

• Medical biotechnology: This field focuses on developing new medical treatments, therapies, and vaccines for a wide range of diseases and conditions.
• Agricultural biotechnology: This field aims to improve crop yields, enhance resistance to pests and diseases, and increase food security.
• Environmental biotechnology: This field uses microorganisms and other biotechnology tools to clean up contaminated sites and to develop new ways to manage waste.
• Industrial biotechnology: This field uses biotechnology to produce chemical products, such as fuels, plastics, and textiles, in a more sustainable and environmentally friendly way.
• Synthetic biology: This is a relatively new field that aims to design and build new biological parts, devices, and systems and to re-engineer existing ones to perform specific tasks.

Each of these fields contributes in unique ways to solving significant problems and improving human health and well-being; all are important in their own right.

How can AI help in biotechnology?

Artificial Intelligence (AI) has the potential to revolutionize the field of biotechnology in several ways. Some of the ways AI can help in biotechnology include:

• Drug discovery and development: AI can help in the discovery and development of new drugs by analyzing large amounts of data and identifying new targets for drug development. It can also help in the design and optimization of clinical trials.
• Predictive diagnostics: AI can help in the early diagnosis of diseases by analyzing patient data, such as medical images and genetic information, to identify patterns and predict the risk of disease.
• Personalized medicine: AI can help in the development of personalized medicine by analyzing large amounts of data to identify the best treatment options for individual patients based on their genetic makeup and medical history.
• Medical imaging: AI can help in the analysis of medical images, such as MRI and CT scans, to identify diseases and guide treatment.
• Bioinformatics: AI can help in the analysis of large amounts of biological data, such as genomic and proteomic data, to identify new targets for drug development and to understand the underlying mechanisms of disease.

These are just a few examples of how AI can help in biotechnology, and the field is rapidly evolving, with new applications and innovations emerging all the time. By leveraging the power of AI, biotechnology has the potential to make significant contributions to human health and well-being.

Top 46 Innovative AI-Enabled Biotech Companies in 2024

The order does not follow a ranking. 

1. Protai

Protai is a biotechnology company that uses the power of proteomics and artificial intelligence to unlock new layers of biological insights and combat complex diseases. With its cutting-edge platform, Protai is leading the charge in revolutionizing how drug candidates are created and validated. By leveraging the latest advances in these fields, Protai can facilitate quicker and more advanced drug discovery, bringing us one step closer to a healthier future.

• Founder(s): Eran Seger, Kirill Pevzner
• Founding year: 2021
• Headquater(s): Tel Aviv, Israel
• Funding: Seed

2. Turbine

Turbine is a biotechnology company that’s changing the way we understand cancer. By creating a platform that delves into the inner mechanisms of this complex disease, Turbine is enabling the discovery of new protein targets, precise biomarkers, and improved patient outcomes. The company’s proprietary Simulated Cell technology, paired with Artificial Intelligence, provides a faster and more comprehensive understanding of therapeutic targets and indications, breaking down the intricacies of cancer like never before.

• Founder(s): Dániel Veres, Kristóf Zsolt Szalay, Szabolcs Nagy
• Founding year: 2015
• Headquater(s): Budapest, Budapest, Hungary
• Funding: Series A

3. LTZ Therapeutics

LTZ Therapeutics is a leading biotech company focused on the development of innovative immunotherapies to improve patient outcomes in cancer and other diseases with unmet clinical needs. LTZ is dedicated to creating cutting-edge immunotherapies that overcome resistance and enhance anti-tumor immunity. 

• Founder(s): Jianhui Zhou, Robert Li
• Founding year: 12021
• Headquater(s): San Francisco, California, United States
• Funding: Seed

4. AI Proteins

AI Proteins is a newly founded biotechnology company focused on designing and engineering synthetic mini-protein therapeutics. They combine cutting-edge computational protein design with advanced laboratory robotics to accelerate the creation of life-changing medicines.

• Founder(s): Carl Novina, Chris Bahl, Marc Cohen
• Founding year: 2021
• Headquater(s): Boston, Massachusetts, United States
• Funding: Seed

5. Terray Therapeutics

Terray Therapeutics is a biotechnology company that propels drug discovery into the information age. It is led by leaders in artificial intelligence, synthetic (medicinal) chemistry, biology, preclinical development, automation, and nanotechnology.

• Founder(s): Eli Berlin
• Founding year: 2018
• Headquater(s): Pasadena, California, United States
• Funding: Series A

6. Engine Biosciences

Engine Biosciences is a venture-backed San Francisco- and Asia-based technology company pioneering network biomedicine. The company’s proprietary and patented technologies are oriented around deciphering biology networks’ complexity include high-throughput wet lab experimentation and artificial intelligence algorithms for drug discovery and cellular reprogramming.

• Founder(s): Jeffrey Lu, Timothy K. Lu
• Founding year: 2014
• Headquater(s): San Francisco, California, United States
• Funding: Series A

7. Great Bay Bio

Great Bay Bio Ltd. is a biopharmaceutical company that utilizes digital technology and AI to shorten the drug development cycle and reduce costs. The company has a long history in biomedical research and development and brings together resources from various regions to form a platform centered on AI, big data, and Internet of Things technology. It aims to take advantage of the strategic concept of scientific and technological innovation in the Greater Bay Area.

• Founder(s): Kingsley Leung, Michael Chen
• Founding year: 2019
• Headquater(s): Sha Tin, New Territories, Hong Kong
• Funding: Series A

8. LinusBio

Linus Biotechnology is a patient-centric, breakthrough science, precision exposome medicine company. Its program pipeline comprises precision exposome medicine biomarkers and target discovery across disease domains. Historically, no molecular endpoints have been available in medical practice or for clinical trials, including CNS (autism spectrum disorder, amyotrophic lateral sclerosis), gastroenterology (inflammatory bowel disease), renal disease, and oncology.

• Founder(s): Manish Arora
• Founding year: 2020
• Headquater(s): New Rochelle, New York, United States
• Funding: Series A

9. Arpeggio Biosciences

Arpeggio Biosciences technology combines a proprietary biological assay and machine learning algorithms that, together, enable rapid, high-resolution snapshots of cellular dynamics following drug treatment. These snapshots are then analyzed to reveal the biological networks that determine a drug’s function and guide therapeutic development.

• Founder(s): Joey Azofeifa, Laura Norris, Tim Read
• Founding year: 2017
• Headquater(s): Boulder, Colorado, United States
• Funding: Series A

10. Unnatural Products Inc.

Unnatural Products Inc is revolutionizing the drug discovery process through the use of machine learning and massively parallel synthesis. By combining these two powerful technologies, Unnatural Products Inc is unlocking the potential of macrocycle drug discovery, which has the potential to create more effective and targeted treatments for a variety of diseases. 

• Founder(s): Cameron Pye, Joshua Schwochert
• Founding year: 2017
• Headquater(s): Santa Cruz, California, United States
• Funding: Seed

11. Lantern Pharma Inc.

Lantern Pharma, Inc. is a clinical-stage pharmaceutical company developing new classes of precision cancer drugs with novel mechanisms of action, and also rescuing or revitalizing abandoned or failed cancer drugs using machine learning techniques, genomic data, and precision oncology trials.

• Founder(s): Arun Asaithambi, Panna Sharma, Peter Nara
• Founding year: 2013
• Headquater(s): Dallas, Texas, United States
• Funding: Post-IPO Secondary

12. CHARM Therapeutics

CHARM Therapeutics delivers transformational medicines through 3D deep learning and cutting-edge drug discovery technologies. By applying revolutionary insights in 3D protein-ligand co-folding, they seek to target previously undruggable disease targets. 

• Founder(s): Laksh Aithani
• Founding year: 2021
• Headquater(s): London, England, United Kingdom
• Funding: Series A. 

13. Ainnocence

Ainnocence is a next-generation biotech aiming to create a self-evolving modularized intelligent platform that integrates various advanced computational and wet lab technologies to revolutionize the drug discovery and development process.

• Founder(s): Lurong Pan
• Founding year: 2021
• Headquater(s): San Francisco, California, United States
• Funding: Seed

14. Accutar Biotech

AccutarBio employs artificial intelligence to revolutionize drug discovery. With capabilities in side chain flexible mode ligand docking, virtual screening, and drug ADME property prediction, Accutar’s platform beats the industry standard in computation-aided drug design.

• Founder(s): Jie Fan, Ke Liu
• Founding year: 2015
• Headquater(s): Shanghai, Shanghai, China
• Funding: Venture – Series Unknown

15. Isomorphic Labs

Isomorphic Labs is a new Alphabet company and commercial venture which aims to reimagine the entire drug discovery process from first principles with an AI-first approach, and, ultimately, to model and understand some of the fundamental mechanisms of life.

• Founder(s): Demis Hassabis
• Founding year: 2021
• Headquater(s): London, England, United Kingdom
• Funding: Unknown

16. Cyclica

As a neo-biotech, Cyclica is efficiently advancing an industry-leading, robust, and sustainable drug discovery portfolio focused on CNS, oncology, and auto-immune diseases. Cyclica has built the only generalizable platform across the entire proteome, expanding the target space for low-data targets, including AlphaFold2 structures, PPIs, and mutant oncogenic targets. Cyclica has brought together a diverse and experienced team of biologists, chemists, computer scientists, and business professionals who are collectively passionate about changing the drug discovery paradigm. By exploring the unexplored, and drugging the undrugged, Cyclica strives to impact patient health like never before. For more information about our company, please visit: cyclicarx.com.

• Founder(s): Naheed Kurji, Jason Mitakidis
• Founding year: 2014
• Headquater(s): Toronto, Ontario, Canada
• Funding: Series B

17. JADBio AutoML

JADBio’s purpose-built AutoML platform provides leading-edge AI tools and automation capabilities, enabling life-science professionals to build and deploy accurate and interpretable predictive models with speed and ease, even if they have no data science expertise.

• Founder(s): Ioannis Tsamardinos, Pavlos Charonyktakis
• Founding year: 2019
• Headquater(s): Los Angeles, California, United States
• Funding: Angel

18. Scailyte

Scailyte is an ETH Zürich spin-off with a best-in-class artificial intelligence platform for the discovery of complex disease patterns from single-cell data. Their solution provides unprecedented insight into diseases and enables ultra-sensitive diagnostics by uncovering human’s hidden “single-cell”​ secrets.

• Founder(s): Daniel Sonnleithner, Dennis Gohlsdorf, Manfred Claassen, Peter Nestorov
• Founding year: 2017
• Headquater(s): Basel, Basel-Stadt, Switzerland
• Funding: Series A

19. Fountain Therapeutics

Fountain Therapeutics is building a pipeline of therapeutics to treat age-related diseases by reversing cellular age. The company has combined the expertise of leaders in aging research and computation to build an AI-driven platform that extracts previously hidden cellular features to measure aging with remarkable precision.

• Founder(s): Joseph Rodgers, Thomas Rando, Tom Cheung
• Founding year: 2017
• Headquater(s): San Francisco, California, United States
• Funding: Series A

20. Aria Pharmaceuticals

Aria Pharmaceuticals is a preclinical-stage pharmaceutical company discovering and developing novel small molecule therapies for complex and hard-to-treat diseases. Aria has redefined the drug discovery approach, saving years in the process and increasing success rates 30 times higher than traditional methods.

• Founder(s): Andrew A. Radin, Andrew M. Radin
• Founding year: 2014
• Headquater(s): Palo Alto, California, United States
• Funding: Series B

21. BioSymetrics

BioSymetrics is a phenomics-driven drug discovery company that integrates clinical and experimental data, using machine learning, to translate human disease biology and advance precision medicines.

• Founder(s): Anthony Iacovone, Gabriel Musso
• Founding year: 2015
• Headquater(s): New York, United States
• Funding: Seed

22. Iktos

Iktos is a start-up company specializing in the development of artificial intelligence solutions applied to chemical research, more specifically, medicinal chemistry and new drug design. Iktos is developing a proprietary and innovative solution based on deep learning generative models, which enables, using existing data, the design of molecules that are optimized in silico to meet all the success criteria of a small molecule discovery project.

• Founder(s): Nicolas Do Huu, Quentin Perron, Yann Gaston-Mathe
• Founding year: 2016
• Headquater(s): Paris, Ile-de-France, France
• Funding: Non-equity Assistance

23. Genesis Therapeutics

Genesis Therapeutics unifies AI and biotech to accelerate the discovery of new medicines. They are combining novel deep neural networks, biophysical simulation, and massively scalable computing infrastructure to achieve industry-leading performance in molecular generation and property prediction.

• Founder(s): Ben Sklaroff, Evan Feinberg
• Founding year: 2019
• Headquater(s): South San Francisco, California, United States
• Funding: Series A

24. Spring Discovery

Spring gives scientists superpowers. They put world-leading technology and easy-to-use software in the hands of researchers working to understand and battle disease. Their mission is to give scientists the best tools in the world to help them fight disease.

• Founder(s): Ben Kamens
• Founding year: 2017
• Headquater(s): Palo Alto, California, United States
• Funding: Series B

25. 1859

1859 is a biotechnology company focusing on the discovery and development of next-generation therapeutics. The company was founded in 2019 and is headquartered in San Diego, California.

• Founder(s): Andrew MacConnell, Devon Cayer, Ramesh Ramji, Sara Thrall Cortese
• Founding year: 2019
• Headquater(s): San Diego, California, United States
• Funding: Series A

How do you measure impact?

1859 is transforming how the Life Science industry discovers new medicines by combining virtual screening, proprietary activity-based small-molecule screening technology, and machine learning to predict the activity of small molecules against biological targets.

Streamlining the medicine discovery process and decreasing the cost of getting a medicine to market will enable pharmaceutical and biotech companies to break down barriers that prevent these companies from targeting diseases that affect small populations and getting medication to populations with a low- to mid-income socioeconomic status.

26. Vilya

Vilya is a cutting-edge computational biotechnology company, co-founded by a team of scientists from the Institute of Protein Design (IPD) led by David Baker, Ph.D., and by ARCH Venture Partners. Vilya creates a novel class of medicines to precisely target disease biology. Their platform is built on ground-breaking research in advanced computational approaches and taps into uncharted chemical space within cyclic peptides to design new molecular structures not found in nature.

• Founder(s): Adam Moyer, Patrick Salveso
• Founding year: 2022
• Headquater(s): Seattle, Washington, United States
• Funding: Series A

27. Persephone Biosciences

Persephone Biosciences develops healthcare technology designed to focus on microbial therapeutics for immuno-oncology applications. The company’s technology uses artificial intelligence and omics techniques on multiple cancer patient gut microbiomes and blood samples to identify microbes needed for normal immune function for population-scale patient data analytics, enabling lab researchers to design microbial drugs that prevent and fight cancer.

• Founder(s): Stephanie Culler, Steve Van Dien
• Founding year: 2017
• Headquater(s): San Diego, California, United States
• Funding: Seed

28. Biotia

Biotia is a health tech company spun out of Cornell Tech leveraging next-generation sequencing and artificial intelligence for rapid precision infectious disease discovery. Their software and laboratory technology enable clinicians and researchers to guide patient treatment and improve health outcomes.

• Founder(s): Chris Mason, Christopher Mason, Niamh O’Hara, Rachid Ounit
• Founding year: 2016
• Headquater(s): New York, New York, United States
• Funding: Series A

29. PostEra

PostEra uses machine learning to close the design-make-test loop of medicinal chemistry to advance drug discovery. The company was founded in 2019 and is based in Boston, MA.

• Founder(s): Aaron Morris, Alpha Lee, Matt Robinson
• Founding year: 2019
• Headquater(s): Boston, Massachusetts, United States
• Funding: Grant

30. Totus Medicines

Totus Medicines is revolutionizing the medical industry with its innovative chemical biology technology. This technology is being used to create life-changing therapies to treat previously untreatable diseases across the entire human genome. These therapies are providing new hope to those suffering from diseases that have been considered incurable.

• Founder(s): Neil Dhawan
• Founding year: 2020
• Headquater(s): Cambridge, Massachusetts, United States
• Funding: Series A

31. Form Bio

Form Bio provides a variety of features, including workflows, data management, collaboration, data visualization, and workflow catalog. It provides solutions for lab directors, biotech, pharma, academics, and other fields.

• Founder(s): Ben Lamm
• Founding year: 2022
• Headquater(s): San Francisco, California, United States
• Funding: Undisclosed

32. Athos Therapeutics Inc

Athos Therapeutics is a late pre-clinical stage biotechnology company pioneering the development of artificial intelligence-based Precision Therapeutics for patients with Inflammatory Bowel, other Autoimmune Diseases, and cancer.

• Founder(s): Allan J. Pantuck, Dimitrios Iliopoulos, Michael Jung
• Founding year: 2019
• Headquater(s): Torrance, California, United States
• Funding: Series A

33. Biolojic Design, Ltd.

Powered by AI, Biolojic is a leading edge company that designs single or multi-specific human antibodies for predefined epitopes. They call these fully human antibodies Multibodies. This creates a significant advantage when trying to bind more than one target with the same mAb or when trying to affect difficult and complex targets.

• Founder(s): Yanay Ofran
• Founding year: 2009
• Headquater(s): Boston, Massachusetts, United States
• Funding: Undisclosed.

34. AI Therapeutics

AI Therapeutics is focused on identifying and developing therapeutics for rare orphan conditions. They accelerate the development process by using a variety of methods to identify and acquire promising pipeline assets – including data mining, deep learning, and in-licensing. 

• Founder(s): Jonathan M Rothberg, Tian Xu
• Founding year: 2013
• Headquater(s): Guilford, Connecticut, United States
• Funding: Series C

35. Eleven Therapeutics

Eleven Therapeutics is a biotechnology company at the forefront of the artificial intelligence revolution in medicinal nucleic acids. The new generation of RNAi therapies is introduced by merging artificial intelligence, parallel functional testing, and combinatorial chemistry. SCSI-RNA is a programmable molecule that can be used to target any disease or biological target of interest.

• Founder(s): Shaul Ilan, Yaniv Erlich, 
• Founding year: 2020
• Headquater(s): Tel Aviv, Tel Aviv, Israel
• Funding: Seed

36. ArrePath

ArrePath is a biotech company discovering and developing new and differentiated classes of anti-infectives to address antimicrobial resistance (AMR) through the application of state-of-the-art technologies and novel strategies.

• Founder(s): Zemer Gitai
• Founding year: 2022
• Headquater(s): Princeton, New Jersey, United States
• Funding: Seed

37. Pepticom Ltd.

Pepticom is a unique Artificial Intelligence (AI) platform company with disruptive technology for peptide discovery. The platform is based on research carried out at the Hebrew University and extensively developed further by the company. Pepticom’s disruptive technology allows for the discovery of quantity and quality innovative peptides and other molecules at a fraction of the time and cost of the traditional laboratory discovery methods.

• Founder(s): Amiram Goldblum, Amit Michaeli, Anwar Rayan, Immanuel Lerner
• Founding year: 2011
• Headquater(s): Jerusalem, Yerushalayim, Israel
• Funding: Venture: Series Unknown

38. Keen Eye by Tribun Health

Every healthcare professional has the responsibility to use the latest tech innovations available to fight diseases. Artificial intelligence can sometimes exceed human expertise by unveiling unseen meaning out of huge amounts of data. At Keen Eye, they strive to make that deeper meaning available to every physician, biologist, and patient.

• Founder(s): Sylvain Berlemont
• Founding year: 2015
• Headquater(s): Paris, Ile-de-France, France
• Funding: Series A

39. METiS Therapeutics

METiS Therapeutics is a biotechnology company that aims to drive therapies in a wide range of disease areas by integrating drug discovery and delivery with AI, machine learning, and quantum simulation.

• Founder(s): Chris Lai
• Founding year: 2017
• Headquater(s): Cambridge, Massachusetts, United States
• Funding: Series B

40. Abiosciences

Abiosciences is focused on harnessing the power of single-cell genomics and bioinformatics to gain molecular insights into human diseases and translate them into effective therapeutics and diagnostics. Their mission is to alleviate human suffering from devastating diseases such as cancer by discovering novel drug targets and therapeutic leads using advanced bioinformatics and single-cell technologies.

• Founder(s): Tony (Dongxiao) Zhang
• Founding year: 2019
• Headquater(s): South San Francisco, California
• Funding: Undisclosed

41. Quris

Quris is an artificial intelligence innovator that is disrupting drug development. Its machine-learning bio-platform better predicts which drug candidates will safely work in humans, avoiding the tremendous costs of failed clinical trials. Quris is led by a track-record team of top scientists and strategic investors. Its first AI-based drug is now prepping for clinical testing.

• Founder(s): Isaac Bentwich, Yossi Haran
• Founding year: 2019
• Headquater(s): Tel Aviv, Tel Aviv, Israel
• Funding: Seed

How do you measure impact?

Quris’ Bio-AI Clinical Prediction Platform better predicts which drug candidates will safely work in humans, avoiding the tremendous costs of failed clinical trials.

Every year 110 million mice and more than 50,000 beagles are sacrificed. Even though, animals are terrible predictors of drug safety because mice and men are very different. Nine out of 10 drugs that enter into clinical trials are failing. And as surprising, as this may sound there is no engine today, or any safety predictor that will do a good job.

At Quris AI we develop a unique model called “Patient on a chip”, which means adding human organs such as a tiny brain, a tiny liver, and a tiny heart (less than a millimeter in size) on a chip. By testing known drugs on these miniaturized patients and collecting massive data, with millions of interactions, documented by nanosensors and microscopy, we train AI to recognize the pattern that sets apart, safe drugs from non-safe drugs. This dramatically reduces the time it takes to develop a drug, saving millions of animals, and helping humans to find a drug that works.

42. ImmunoMind

ImmunoMind is a UC Berkeley SkyDeck alumnus company focused on identifying complex cell populations with desired properties (e.g., proliferation potential or exhaustion rate) in drug development and manufacturing of cell therapies. ImmunoMind leverages a proprietary multi-omics database of CAR-T cells to help design and produce safer and more effective CAR-T therapies.

• Founder(s): Sergey Fedyushchenko, Vadim Nazarov, Vasily Tsvetkov
• Founding year: 2018
• Headquater(s): Berkeley, California, United States
• Funding: Pre-Seed

43. Imagene AI

Imagene was founded with a clear mission to leverage AI to profile, within minutes, a broad range of biomarkers from a digitized biopsy image alone. By doing so, we can overcome economic, logistical, and technological barriers to reach the full potential of precision medicine for all cancer patients.

• Founder(s): Dean Bitan, Jonathan Zalach, Shahar Porat
• Founding year: 2020
• Headquater(s): Tel Aviv, Tel Aviv, Israel
• Funding: Series A

44. TeselaGen Biotechnology

TeselaGen’s artificial intelligence-powered enterprise platform is used for designing, building, testing, and optimizing biological systems. The platform radically accelerates product development of therapeutics, vaccines, sustainably sourced chemicals, and agricultural products.

• Founder(s): Eduardo Abeliuk, Michael Fero, Nathan Hillson
• Founding year: 2011
• Headquater(s): Portola Valley, California, United States
• Funding: Undisclosed

45. DeepCure

DeepCure was founded to accelerate breakthrough science, developed by world-leading AI engineers, data scientists, and biologists. Their founding team includes some of the industry’s preeminent drug-discovery scientists and technologists. DeepCure vision is to use AI-driven discovery to create better molecules and faster cures for every disease-relevant protein target.

• Founder(s): Joseph Jacobson, Kfir Schreiber
• Founding year: 2018
• Headquater(s): Boston, Massachusetts, United States
• Funding: Series A.

46. Relation Therapeutics

Relation is pioneering a “Lab-in-the-Loop” that can integrate active learning at every step of drug discovery, from predicting cell states to the validation of new targets. Working from real cells provided by proprietary biobanks, Relation’s technology generates genomic data that provide direct insights into critical biological relationships that are fed directly into its ML systems.

• Founder(s): Benjamin Swerner, Charles Roberts, Jake Taylor-King
• Founding year: 2019
• Headquater(s): London, England, United Kingdom
• Funding: Seed